Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II study evaluating HLX43 for efficacy and safety in patients with hormone receptor-positive, HER2-negative locally…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING